INTRODUCTION
Despite technical advances in cataract surgery, the use of new intra-ocular lenses (IOL) with sharp edge design, and new biomaterials, the most common complication of cataract surgery is still posterior capsule opacification (PCO). [1] [2] [3] [4] Neodymium: yttrium aluminum garnet (Nd: YAG) laser posterior capsulotomy has been used successfully to treat PCO. [5] Various complications such as retinal detachment, temporary increase in intra-ocular pressure (IOP), IOL damage, uveitis, and cystoid macular edema may occur. [6] [7] [8] Increase in IOP manifests itself particularly within the first 3 hours, and though it usually heals without sequelae, it may cause loss of vision or visual field, especially in patients with glaucoma. [9] Topical apraclonidine 0.5%-1%, brimonidine 0.2%, timolol maleate 0.5%, and combinations of brimonidine-timolol or dorsolamid-timolol can be used to prevent increase in IOP, and generally any increase in IOP after laser procedure can be brought under control. [10] [11] [12] [13] The aim of the present study was to analyze the effect of topical brimonidine use on IOP and changes in IOP in patients who did not receive prophylaxis drug.
MATERIAL AND METHODS
The study included 40 eyes of 40 patients whose pre-laser IOP value was less than 18 mmHg as measured with Goldmann applanation tonometry, and on whom posterior capsulotomy was performed due to PCO. Written, informed consent was obtained from patients after having informed them about all possible complications prior to the procedure. This study was approved by the Hospital Ethics Board (March 11, 2014 Etik Kur.89513307/1009/240). Patients were divided into 2 groups: Group A and Group B. Both groups were comprised of 12 female and 8 male patients; mean age in Group A was 60.8±12.4 years, and mean age in Group B was 59.9±13.2 years. Pupil dilation in all patients was ensured with application of tropicamide 0.5% (Tropamid) 30 minutes prior to the laser procedure. Five minutes before the procedure, topical anesthesia was obtained with proparacaine drop (Alcaine). Topical brimonidine (Alphagan P) was applied 1 hour prior to laser and right after laser to patients in Group A; as control group, no drug was applied to the 20 patients in Group B. Prelaser, first hour post-laser, first day post-laser, and first week IOP values of patients were calculated with applanation tonometry. Nepafenac drops (Nevanac) were applied to all patients 3 times a day for 1 week. With the help of capsulotomy lens, capsulotomy was performed on optic axis area in a (+) shape with low power, starting at 1.2 mJ. Mean power was 15.3±3.6 mJ in Group A and 15.4±3.6 mJ in Group B; mean number of shots in Group A was 12.8±5.2 and 12.9±5.1 shots in Group B. Patient demographics before laser procedure are provided in Table 1 . All values were evaluated statistically using SPSS software (Statistical Package for Social Sciences version 22.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Mean pre-laser IOP value was 14.7±3 mmHg in Group A and 14.6±3.9 mmHg in Group B. Initially, there was no statistically significant difference between the 2 groups (Mann-Whitney U test; p>0.05). Mean post-laser IOP measurements at first hour, first day, and at first week postprocedure were 12.7±3.3 mmHg, 13.7±2.3 mmHg, and 14.2±2.3 mmHg, respectively, in Group A, and 15.1±2.9 mmHg, 14.9±2.1 mmHg, and 14.5±2 mmHg in Group B (Figure 1 
DISCUSSION
PCO can be successfully treated with Nd: YAG laser posterior capsulotomy and a satisfactory increase in visual acuity can be ensured. IOP increase after Nd: YAG laser is a complication reported at various intervals. [14] Studies in the literature indicate the efficiency of various anti-glaucomatous agents in the control of IOP. It was reported in a study by Ateş et al. that they provided early IOP control with 1 week of brimonidine use after prophylactic apraclonidine and that they found first hour and first day IOP values in the control group significantly high. [15] Similarly, Singhal et al. stated that with prophylactic use of brimonidine they saw a significant decrease in IOP values when compared to the control group. [16] There are also studies in the literature reporting that a significant change was not detected in IOP values after laser capsulotomy. Yazıcı et al. stated that they did not detect a significant change in post-laser IOP values with regard to pre-laser values. [17] In another study, Özkurt et al. indicated that they did not detect a significant increase in first day, first month and third month IOP values after YAG laser capsulotomy compared to pre-laser values. [18] In the present study, there was no significant increase in the group where brimonidine was not used; however, in the group where prophylactic brimonidine was applied, post-laser first hour and first day IOP values were statistically significantly lower compared to pre-laser values and control group values. The reason for these varied results may be total power used in YAG laser and difference in the number of shots. There are articles in the literature reporting different results regarding the effect on IOP increase of the number of shots and total power used. Kaur et al. reported that they achieved significant IOP control with prophylactic apraclonidine compared to control group and that they did not find a relationship between IOP increase and total power. [19] In another article, Cumurcu and Etikan stated that IOP increase had correlation to the number of shots and total power used. [20] In the present study, use of prophylactic brimonidine provided a significant decrease with regard to pre-laser IOP values, and low power and few shots were used. There was no significant increase in IOP in patients with normal pre-laser IOP values.
In conclusion, YAG laser posterior capsulotomy can be used as a safe method to treat PCO. In the present study, along with not observing a significant IOP increase in the group where prophylactic brimonidine was not used, efficient IOP control was provided in the group where brimonidine was used. The number of shots applied during laser procedure, total power used, and the level of postprocedure inflammation suppressed with an agent can be important factors affecting IOP changes after YAG laser. Additional studies are needed to evaluate the effects of these factors on IOP changes after YAG laser posterior capsulotomy. 
